iiinova — where your digital self keeps evolving

Arvind Suresh

@arvindsuresh1.bsky.social

IM PGY-2 @UCSF | @GeiselMed '23 | @Dartmouth '19 | Aspiring hematologist/oncologist interested in myeloma #MMsm, cell therapy, med ed & health equity | he/him

Posts Replies Media

Arvind Suresh @arvindsuresh1.bsky.social · 18/10/2025

How should we choose optimal salvage treatments following BCMA-directed CAR-T therapy in multiple myeloma? Check out our review article out today summarizing recent studies and our approach to therapy sequencing from our team at @ucsfcancer.bsky.social #MMsm #myeloma dx.doi.org/10.1080/1750...

Our strategy to address relapse after BCMA CAR T-cell therapy depends on whether a patient has rapid aggressive relapse (i.e., extramedullary disease, plasma cell leukemia, or rapidly rising myeloma markers or disease burden) or biochemical/clinical relapse without aggressive features. For all patients, talquetamab or another GPRC5D bispecific is a preferred approach. For rapid aggressive relapse, high dose cytotoxic chemotherapy or salvage autologous stem cell transplant may also be considered. For other relapses, a retrial of BCMA targeted therapy or various proteasome inhibitor and immunomodulatory drug combinations can be considered. The rapidly changing landscape of available drugs means that several novel approaches or clinical trials may also be available for patients.

131

Arvind Suresh @arvindsuresh1.bsky.social · 28/04/2025

I enjoyed working with colleagues and mentors at Dartmouth to create and lead these workshops for medical students and faculty to develop skills in addressing microaggressions and bias in their roles as health care professionals, educators, and leaders. Learn more below👇 @aamctoday.bsky.social

012

Reposted by Arvind Suresh

ASTCT @astct.bsky.social · 15/02/2025

At #Tandem25: @drkomanduri.bsky.social accepts the ASTCT advocacy award. Congratulations Dr. Komanduri, we commend you for your dedication to advancing our field!

1124

Arvind Suresh @arvindsuresh1.bsky.social · 26/12/2024

Grateful to Clinical Lymphoma, Myeloma & Leukemia, co-authors, and @ash-hematology.bsky.social for the opportunity to share this research on targeted neurocognitive testing after anti-CD19 and anti-BCMA #CART cell therapy. #lymsm #mmsm clinical-lymphoma-myeloma-leukemia.com/article/S215...

110